More importantly, in the joint analysis of ICIs (anti-PD-1 and anti-CTLA-4 antibodies), immunotherapy will provide greater therapeutic benefit to low-risk GC patients, leading to superior outcomes. This evidence concerns the gene PDCD1 and gastric cancer.